Merus NV
NASDAQ:MRUS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
22.86
60.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MRUS stock under the Base Case scenario is 25.52 USD. Compared to the current market price of 50.81 USD, Merus NV is Overvalued by 50%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Merus NV
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MRUS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Merus NV
Balance Sheet Decomposition
Merus NV
Current Assets | 666.3m |
Cash & Short-Term Investments | 632.3m |
Receivables | 3.9m |
Other Current Assets | 30.1m |
Non-Current Assets | 178.4m |
Long-Term Investments | 150.6m |
PP&E | 22.5m |
Intangibles | 1.9m |
Other Non-Current Assets | 3.5m |
Current Liabilities | 80.1m |
Accounts Payable | 6.2m |
Accrued Liabilities | 38m |
Other Current Liabilities | 35.9m |
Non-Current Liabilities | 61.3m |
Other Non-Current Liabilities | 61.3m |
Earnings Waterfall
Merus NV
Revenue
|
35.9m
USD
|
Operating Expenses
|
-266.9m
USD
|
Operating Income
|
-231m
USD
|
Other Expenses
|
-13.6m
USD
|
Net Income
|
-244.6m
USD
|
Free Cash Flow Analysis
Merus NV
USD | |
Free Cash Flow | USD |
MRUS Profitability Score
Profitability Due Diligence
Merus NV's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Merus NV's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
MRUS Solvency Score
Solvency Due Diligence
Merus NV's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Merus NV's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRUS Price Targets Summary
Merus NV
According to Wall Street analysts, the average 1-year price target for MRUS is 90.78 USD with a low forecast of 67.67 USD and a high forecast of 116.55 USD.
Dividends
Current shareholder yield for MRUS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MRUS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 121 full-time employees. The company went IPO on 2016-05-19. The firm develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Officers
The intrinsic value of one MRUS stock under the Base Case scenario is 25.52 USD.
Compared to the current market price of 50.81 USD, Merus NV is Overvalued by 50%.